On Wednesday, Following Stocks were among the “Top Priority Stocks” For Traders – Akorn, Inc (NASDAQ:AKRX), XOMA Corp (NASDAQ:XOMA), PMC-Sierra Inc (NASDAQ:PMCS), AMAG Pharmaceuticals, Inc (NASDAQ:AMAG)
Akorn, Inc (NASDAQ:AKRX)’s shares dwindled -5.19%, and closed at $45.66. The stock volatility for the week is 4.76%, while for the month remained 5.96%. The corporation holds consensus target price of $57.69.
If we consider EPS growth of the corporation, then the corporation indicated the following observations:
The corporation showed 0.30 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -26.10% and Annual EPS growth for the past 5 years is considered as 26.30%.
The mean recommendation of analysts for this stock is 1.90. (where 1=Buy, 5=Sale).
Akorn, Inc. develops, manufactures, and markets generic and branded prescription pharmaceuticals, in addition to animal and over-the-counter (OTC) consumer health products in the United States and internationally. It operates through two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment markets generic and branded ophthalmics, injectables, oral liquids, otics, topical, inhalants, and nasal sprays. This segment’s generic products comprise Clobetasol Propionate, a corticosteroid, which is used to treat various skin conditions; Fluticasone Propionate, a corticosteroid used for nasal symptoms of allergic and non-allergic rhinitis conditions; Lidocaine/Prilocaine, a topical anesthetic; Progesterone, which is used to prevent endometrial hyperplasia; Vancomycin, an antibiotic used to treat bacterial infections; and other products.
XOMA Corp (NASDAQ:XOMA), declined -5.13%, and closed at $3.70. The corporation holds the market capitalization of $453.13M. For the last twelve months, the stock was able to keep return on equity at 733.00 %, while return on assets at -42.80%, in response to its return on investment at -211.90%. Its 20-day moving average declined -2.95%, above 50-day moving average of 0.75%, below 200-day moving average of -10.65% from the latest market price of $3.70. The mean recommendation of analysts for this stock is 1.80.(where 1=Buy, 5=Sale).
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The corporation’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
PMC-Sierra Inc (NASDAQ:PMCS), dipped -4.50 %, and closed at $9.12. The corporation has the market capitalization of $1.90B. The beta value of the stock is 1.28. On the other hand the stock’s volatility for the week is 2.42%, and for the month is 1.94%. The stock’s price to book ratio is 2.90, however price to sale ratio is 3.51. Analyst’s mean recommendation regarding this stock is 2.90. (where 1=Buy, 5=Sale).
PMC-Sierra, Inc. designs, develops, markets, and supports semiconductor solutions for communications network infrastructure equipment worldwide. Its semiconductor devices enable networking equipment primarily in three markets, counting storage, optical, and mobile networks. The corporation’s storage products comprise RAID-on-chip, protocol controllers, flash controllers, host bus adapter and serial attached small computer system interface expanders, and MIPs processors that enable high-speed communication servers, switches, and storage devices to store, manage, and move large quantities of data securely. Its optical products comprise wide area network communication products focusing on metro and access networks, counting optical transport network, synchronous optical networks, asynchronous transfer mode, and fiber to the home; and ethernet framers, mappers, MAC, synchronous digital hierarchy framers, cross connects, and T1/E1 mappers/framers, in addition to EPON/GPON ONU and OLT processors.
AMAG Pharmaceuticals, Inc (NASDAQ:AMAG), dropped -5.08%, and closed at $54.01. The stock has price to sale ratio of 12.84, however, price to book ratio is 2.81. With recent decline, the year-to-date (YTD) performance reflected a 26.72% gain below last year. During the past month the stocks gain 22.25%, bringing three-month performance to 24.39% and six-month performance to 138.67%. The mean recommendation of analysts for this stock is 1.60. (where 1=Buy, 5=Sale).
AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical corporation that focuses on maternal health, anemia, and cancer supportive care. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women with a singleton pregnancy; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the administration of oral mucocitis/stomatiits and various types of oral wounds. The corporation markets Feraheme in the United States and Canada; and as Rienso in the European Union. It sells Feraheme to authorized wholesalers and specialty distributors. The corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve talk aboutions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as anticipates, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
